Skip to content
In English |
En español
Search
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-25 of 66 for your search:
Drug:
alemtuzumab
Find trials that include:
Any drugs shown
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Phase II/III Randomized Study of Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
Phase:
Phase III, Phase II
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
Any age
Sponsor:
Other
Protocol IDs:
UHW-AML16
, EU-20677, ISRCTN11036523, EUDRACT-2005-002846-14, MREC-CU106, NCT00454480
2.
To Determine the Role of Adding Campath-1H or ATG Given in-Vivo in Addition to Fludarabine and Low Dose Busulfex on Outcome in Patients Treated With Reduced Intensity Conditioning
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
230704-HMO-CTIL
, NCT00226512
3.
Budesonide for Prevention of Acute Gastrointestinal GVHD Following Allogenic Stem Cell Transplantation
Phase:
Phase III
Type:
Supportive care, Treatment
Status:
Active
Age:
12 to 65
Sponsor:
Other
Protocol IDs:
PROGAST
, NCT00180089
4.
Alemtuzumab and CHOP in T-cell Lymphoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 to 65
Sponsor:
Other
Protocol IDs:
2006-006130-17
, NCT00646854
5.
Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
61 to 80
Sponsor:
Other
Protocol IDs:
DSHNHL 2006-1B / ACT-2
, BMBF GFVT 01014715, NCT00725231
6.
Phase I/II Study of Alemtuzumab-Based Conditioning Followed By HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Advanced Mycosis Fungoides/Sezary Syndrome
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 to 70
Sponsor:
NHLBI
Protocol IDs:
NHLBI-02-H-0250
, NCT00047060
7.
Stem Cell Transplant for Hematologic Diseases and Renal Cell Cancer
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
70 and under
Sponsor:
Other
Protocol IDs:
H8713
, NCT00058825
8.
Phase I/II Pilot Study of Alemtuzumab and Cyclosporine in Patients With Myelodysplastic Syndromes
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 to 72
Sponsor:
NHLBI
Protocol IDs:
NHLBI-05-H-0206
, NCT00217594
9.
Weekly Subcutaneous Alemtuzumab and Rituximab for Relapsed CLL
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
05-404
, NCT00330252
10.
Phase I/II Study of Alemtuzumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (CHOP) Chemotherapy in Patients With Newly Diagnosed, Stage II-IV Aggressive Peripheral T-Cell Non-Hodgkin's Lymphoma
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
TSRCC-164-2006
, NCT00363090
11.
Phase I/II Randomized Pilot Study of Targeted Immune-Depleting Chemotherapy, Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation from an HLA-Matched Unrelated Donor, and Graft-Versus-Host Disease Prophylaxis Comprising Tacrolimus, Methotrexate, and Sirolimus Versus Alemtuzumab and Cyclosporine in Patients With High-Risk Advanced Hematologic Malignancies or Other Diseases
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 to 69
Sponsor:
NCI
Protocol IDs:
NCI-07-C-0195
, 07-C-0195, NCT00520130
12.
Phase I/II Study of Alemtuzumab, Bulsulfan, and Cyclophosphamide Followed by HLA-Mismatched Unrelated Peripheral Blood Stem Cell Transplantation in Patients With Hematologic Cancer
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
50 and under
Sponsor:
NCI
Protocol IDs:
FHCRC-1981.00
, 6508, NCT00555048
13.
Phase I/II Study of Reduced-Intensity Preparative Regimen Comprising Fludarabine, Busulfan, and Alemtuzumab Followed By Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematological Malignancies or Other Diseases
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
70 and under
Sponsor:
Other
Protocol IDs:
BCM-H-19386
, BCM-FAB, H 19386, NCT00625144
14.
Phase I/II Pilot Study of a Nonmyeloablative Conditioning Regimen Comprising Anti-CD45 Monoclonal Antibody, Alemtuzumab, Fludarabine Phosphate , and Low-Dose Total-Body Irradiation Followed by Allogeneic Hematopoietic Stem Cell Transplantation in Patients With High-Risk Hematological Diseases
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
Under 100
Sponsor:
Other
Protocol IDs:
BCM-H-12472
, H 12472, BCM-ACHE, NCT00056966
15.
Phase I/II Study of Consolidation Therapy With Alemtuzumab in Patients With B-Cell Chronic Lymphocytic Leukemia Who are in Complete or Partial Second Remission After Fludarabine Phosphate- or Bendamustine Hydrochloride-Based Cytoreductive Therapy
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other, Pharmaceutical / Industry
Protocol IDs:
GCLLSG-CLL2I
, CLL2I, BAYER-GCLLSG-CLL2I, EU-20816, NCT00634881
16.
Unrelated Hematopoietic Stem Cell Transplantation(HSCT) for Genetic Diseases of Blood Cells
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
21 and under
Sponsor:
Other
Protocol IDs:
CCI #07-00119
, CHLA-#07-00119, NCT00730314
17.
Alemtuzumab (CAMPATH 1H) Associated to G-CSF in Adult Patients With Refractory Acute Lymphocytic Leukemia
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
Over 15
Sponsor:
Other
Protocol IDs:
P051003
, RAF 06003, ENR060323, NCT00773149
18.
Everolimus and Alemtuzumab in Treating Patients With Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
NCI-2009-00935
, MC088C, NCT00935792
19.
Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
12175A
, NCT00943293
20.
Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
13437B
, NCT00943319
21.
Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 to 75
Sponsor:
Other
Protocol IDs:
14341B
, NCT00943592
22.
Bendamustine Combined With Alemtuzumab in Pretreated Chronic Lymphocytic Leukemia (CLL)
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
AGMT CLL-6 BendAlem
, NCT00951457
23.
Alemtuzumab and Clofarabine for Relapsed or Refractory Acute Lymphoblastic Leukemia
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
16 to 120
Sponsor:
Other
Protocol IDs:
090331
, NCT00983528
24.
Phase II Study of Pentostatin, Cyclophosphamide, and Rituximab Followed By Alemtuzumab in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
ECOG-2903
, NCT00074282, E2903
25.
Phase II Study of a Nonmyeloablative Conditioning Regimen Comprising Alemtuzumab, Fludarabine, and Low-Dose Total-Body Irradiation Followed by Immunosuppression Comprising Cyclosporine and Mycophenolate Mofetil in Patients Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation for Hematologic Malignancy
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
Under 75
Sponsor:
NCI
Protocol IDs:
FHCRC-1959.00
, 5952, NCT00118352
Select All on Page
1
Help with Results
NCI Home
|
Text-Only Version
|
Contact Us
|
Policies
|
Accessibility
|
RSS
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute
